R.M. Galindo-Suárez

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico

OBJECTIVE Therapies for end-stage renal disease improve quality of life, and survival. In Mexico, clinicians often must choose between different therapies without the availability of comparative outcomes evaluation. The present study evaluates the comparative cost-utility of sirolimus (SIR) versus tacrolimus (TAC) for the primary prevention of graft rejection in renal transplant recipients in Mexico. METHODS We used modeling techniques to estimate the cost-effectiveness of SIR versus TAC to prevent graft rejection in patients with end-stage renal disease in the Mexican setting. The model estimates the cost of quality-adjusted life-year (QALY) per patient. We applied a 20-year horizon (1-year Markov cycles). Cost-effectiveness was expressed in terms of cost per QALY. All costs are presented in 2011 US dollars. Probabilistic sensitivity analyses were conducted. RESULTS The total cost for the SIR treatment arm over the 20-year duration of the model is estimated to be

Costo Efectividad del Tratamiento de Tumores Neuroendocrinos Pancreaticos Avanzados no Operables con Sunitinib en Mexico

136,778. This compares with

Health care costs of osteopenia, osteoporosis, and fragility fractures in Mexico

142,624 for the TAC treatment arm, resulting in an incremental cost of SIR compared with that of TAC of-

PUK20 Cost-Utility Assessment of Sirolimus Versus Tacrolimus for Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico

5,846. Over 20 years, SIR was estimated to have 8.18 QALYs compared with 7.33 QALYs for TAC. The resulting incremental utility of SIR compared with that of TAC is 0.84 QALY gained. SIR is estimated to be both less costly and more effective than TAC, indicating that it is the dominant strategy. Notably, results suggest that SIR has a 78% probability of being dominant over the TAC strategy and a 100% probability of having an incremental cost-effectiveness ratio at or below

[Cost-effectiveness analysis of etanercept compared with other biologic therapies in the treatment of rheumatoid arthritis].

10,064 (1 GDP) per QALY. CONCLUSIONS These analyses suggest that in the Mexican setting, the use of SIR in place of TAC for the prevention of graft rejection in this population is likely to be cost saving.

Análisis del costo y la efectividad de los esquemas de administración de factores de coagulación para el manejo de niños con hemofilia A en México

OBJECTIVES Sunitinib had showed a substantial clinical benefit in patients with non-resectable pancreatic Neuroendocrine Tumors (NET). The objective of this study was to estimate the cost-effectiveness of sunitinib in the treatment of non-resectable pancreatic NET, from the perspective of the Social Security Mexican Institute (IMSS). METHODS A Markov model (2-week cycles) was used to estimate the health and economic consequences of sunitinib 37.5mg/day+best supportive care (BSC) regarding placebo+BSC (ten-years horizon, discount rate: 5%). Effectiveness measures were: overall survival (OS), progression-free survival (PFS) and quality adjusted life years (QALY). Resource utilization (BSC, adverse events management, medical follow-up) was estimated through a survey with Mexican oncologists (n=10). Unit costs of medication and medical resources were obtained from institutional sources. Sensitivity analyses were performed and acceptability curves were constructed. RESULTS Sunitinib+BSC gained 0.49 years (PFS), 1.18 years (OS) and 0.70 QALY against placebo+BSC. Sunitinib+BSC increased medical direct costs (2011 US

PSY30 Cost Utility Analysis of the Profilaxis Versus On-Demand Treatment With Recombinant Factor IX for the Treatment of Hemophilia B in Mexico

) per patient in

Economic Assessment Of Gemifloxacin For The Management Of Acute Exacerbations Of Chronic Bronchitis In Mexico

20,854, which was driven by acquisition costs of sunitinib and medical follow up before progression. ICERs were

Estimación De La Prevalencia De Artritis Reumatoide En México

42,157,

Impacto Financiero Del Tratamiento Farmacológico En Pacientes Adultos Con Enfermedad De Gaucher Tipo 1 En México

17,662 and